World's Top Billionaires Invest in the Biggest Cancer Breakthrough Since Chemo

This could go down as the biggest market story in history. You must act on this urgent wealth-creation event soon...

"The whole cancer world's going to be changed forever."

— Dr. Carl June, University of Pennsylvania medical school

double-down-arrow-white

Dear Reader,

Forget chemotherapy...

Forget radiation...

And forget invasive surgery...

“The FDA just approved a game-changing cancer treatment,” says Popular Science. 

Even the FDA called the approval “historic.”

As FDA commissioner Scott Gottlieb says: “We’re entering a new frontier in medical innovation.”

A revolutionary medical treatment that literally kills cancer in a single shot...

As Mark Trusheim, director of the MIT Center for Biomedical Innovation, says of this therapy: “[It’s] different because you’re treated once and then you’re done, as compared to regular drugs where you take them every month or every day.”

Dr. Gene Saylors, an oncologist in Charleston, South Carolina, says: “It has dramatically changed the way we treat patients.”

“We’re saving patients who three or four years ago we were at our wit’s end trying to keep alive,” says University of Pennsylvania's Dr. Stephen Schuster.

For instance, this breakthrough cured former President Jimmy Carter of stage 4 melanoma that had spread to his brain.

It zapped his cancer in just four months!

He calls it his “key to success.”

  • Popular Science hails it as “a new era for cancer treatment.”
  • The Guardian calls it “the most exciting development in cancer treatment in years.”
  • “The list of cancers that can be treated [by this therapy] keeps growing,” says the Washington Post.

But here’s perhaps the best part about it...

Dr. Roy Herbst, chief of medical oncology at Yale Cancer Center says it could replace chemotherapy as the “standard treatment” for cancer within the next five years.

“You can see a response as quickly as a couple weeks. Some patients have amazing survival,” says Herbst.

This could go down as the biggest health care breakthrough of the 21st century.

Former New York City Mayor Michael Bloomberg, who has a net worth of nearly $50 billion, and Silicon Valley billionaire Sean Parker have already poured hundreds of millions of dollars into research for this treatment with the goals of perfecting it for every form of cancer and bringing it to the world.

In fact, Sean Parker, Facebook’s first president, has invested a whopping $250 million.

Bill Gates has also invested $40 million into this breakthrough. And when it comes to science, Gates only puts his money into sure things.

As Gates says of his foundation’s work: “[Global health is] the starting point of our philanthropy, and it’s the majority of what we do.”

Even Jeff Bezos, CEO and founder of Amazon, has plunked down $35 million.

These top billionaires are investing in this breakthrough. So, why shouldn’t you?

In a moment, I’m going to show you how you can get a piece of the action, too, and ride it for the biggest payday of your life.

Are you ready for the chance to become richer than you ever could have imagined?

Well, get ready...

Because this could be the answer that allows treatments for prostate cancer, breast cancer, lung cancer, leukemia, lymphoma — all cancer, at all stages.

That’s why I’m about to give you the full story on this game changer right now...

In fact, it’s award winning!

"The cancer was just melting away."

The American Society of Clinical Oncologists (ASCO) awarded this breakthrough the Clinical Cancer Advance of the Year for the second straight year!

As Dr. Julie Vose, the president of the ASCO, says: “No recent advance has been more transformative than the rise of [this therapy].”

That’s quite the ringing endorsement. And it’s no wonder...

Take 69-year-old Ben Kelvin from Spokane, Washington.

His body was swollen with lymphoma.

Treatment after treatment failed.

But then, the doctors administered a radical approach...

They gave Ben this single-shot cancer-blasting therapy.

Looking in the mirror, Ben saw that “the cancer was just melting away.”

Just one month after receiving the one-time infusion, the doctors couldn’t find a single trace of lymphoma in Ben’s body.

“I’m in full remission — how wonderful is that?” said Ben.

And Ben isn’t the only cancer patient to have experienced life-changing results with this treatment.

“I was given 12 months to live,” says Andrew Collins, a 52-year-old from Lubbock, Texas.

His melanoma had spread to his lungs, bowel, liver, and spine.

With no alternatives left, Andrew was given the experimental single-shot cure.

And like magic, his tumors shrank and shrank.

His doctor told him that he was clear of cancer, just two months later.

“I’m in a very happy place,” said Collins.

It’s truly a miracle in every sense of the word.

Doctors across America are stunned by its effectiveness:

  • “We’re seeing tumors and leukemias disappear over weeks,” says Dr. Stanley Riddell of the Fred Hutchinson Cancer Center in Seattle.
  • “We are at the forefront of an emerging and promising field of cancer research and treatment,” says Dr. Paul Rothman, dean and CEO of Johns Hopkins Medicine in Baltimore.

  • And Dr. Duane Mitchell, director of the University of Florida Brain Tumor Program calls it “a paradigm shift in clinical oncology as what may become the mainstay of cancer treatment.”

In a moment, I’m going to share more details about this lifesaving cancer breakthrough...

And the extraordinary 893% gains that you stand to collect by getting in early on this medical revolution...

But first, it’s important for you to know who I am and why I’ve never been more certain about anything else in my career.

Hi, My Name Is Charles Mizrahi

double-down-arrow-white

I’m not a physician.

iwp-mizrahi

And I didn’t go to medical school.

But I was a founder of a charitable organization for a major hospital in Brooklyn, New York.

I’ve also been a trader, money manager, and market timer for the past 30 years.

I started my career on Wall Street at age 20.

I remember bumping into traders like Paul Tudor Jones long before anyone knew who he was — before he famously shorted the crash of ’87 and before he built his billion-dollar fortune.

When I ran my money management firm, Hampton Investors, the likes of Goldman Sachs, Citicorp, Credit Suisse, and other legendary Wall Street banks ponied up my $1 million minimum to have me manage their money.

Bear in mind that these guys are wealth managers in their own rights. But the fact remains that they chose me to manage many of their millions.

We did pretty well, too.

I was ranked the No. 1-performing market timer, not just on Wall Street but in the entire U.S., based on the actual performance of client accounts.

Later, Barron’s ranked me its No. 1 money manager.

Over a one-year period, I netted my clients a 113% return. Over three years, I brought in 313%.

So, I know firsthand what it’s like to manage a $200 million portfolio during both market booms and busts.

I made money as a pro trader during the go-go ’80s, watched fear grip Wall Street in ’87, and also invested through the booming ’90s, the dotcom bubble and bust, the housing bubble, the ’08 financial recession, and the strong bull market that followed.

I’ve seen it all.

And not as a bystander but instead from the inside of Wall Street as a trader, money manager, hedge fund manager, and manager of my own personal wealth.

I’ve gone on runs where I’ve picked as many as 36 stocks in a row that have gone up 50% or more.

I’ve gone as long as two entire years of active investing without a single losing position.

In total, my stock-picking method has generated massive raw returns of 3,402% for my readers.

And it’s the same methodology that I use for picking stocks in my own personal portfolio.

For instance, I uncovered a company called Huntington Ingalls Industries back in February 2013. I’m currently up 341% on the stock, and I'm expecting it go much higher:

paic-cancer-blaster-huntington

I’m also up 297% on Google:

paic-cancer-blaster-google

And I’m sitting on gains of 231% in Onex Corporation:

paic-cancer-blaster-onex

These three stocks could have made you combined gains of 869%.

Now, I’m not showing you these gains to brag...

But rather, to prove to you that when it comes to identifying and seizing opportunities — like this monumental breakthrough in the war against cancer — I know what I’m doing...

"The Best Class I've Taken, Period"

The market is projected to reach $202 billion a year in sales by 2021.

That’s 231% growth over the next three years!

Imagine what you could do with those kinds of profits. Perhaps, you could use that newfound money to retire earlier than you ever thought possible and buy that dream house you’ve always wanted.

Or you could donate it to charitable causes that are close to your heart. That’s what’s important to me. And that’s what I did.

The fact is that I left Wall Street because I couldn’t sit through another meeting where my coworkers discussed how to part the elderly from their pensions or swindle novice investors to get ahead.

Because that’s what really happens. They don’t care whether or not you make money — they only care how fat their own wallets get.

I just didn’t want to be a part of it anymore.

Today, I have the privilege of spending more time watching my kids grow up and being a part of their lives. Instead of traveling around the world on business or working late nights and weekends, I enjoy traveling with my wife and taking my children on extended vacations.

I also taught an investing course at the New York University School of Continuing Education and Professional Studies. One of my students is now in charge of managing and allocating $9.5 billion for one of the largest multinational banks in the world.

He wrote a note to me saying:

Your class is probably the best I have taken, period... Professors I consider great do an excellent job of breaking down complicated things to very simple terms and apply everything taught to real life examples. I think you do an excellent job at both.

Of course, I’m still an investor. I still have every bit of 35 years worth of knowledge and trading tricks up my sleeve. And I’m still a teacher, too. Except now, I teach a community of everyday investors how to build extraordinary wealth.

But in the spirit of full disclosure, I’d like to point out a few things about my upbringing and my early years on the Street...

You see, I didn't kick off my career with a silver spoon in my mouth and a million dollars in seed capital from my father.

In fact, my father was a warehouse manager and my family was middle class. The six of us crowded into a modest home and shared one bathroom.

Now, my brothers and I didn’t go to bed hungry at night, but we also didn't have much to spare.

So, when I voiced my goal — to work on Wall Street — to my parents, I had their unconditional support. But that was all the help they could afford to give me.

Oddly enough, I owe my start on Wall Street to my grandmother. I had to borrow money from her just to afford my seat on the exchange!

Without my grandmother's generosity, I'd never be where I am today. And perhaps that's why I couldn't stomach all the Wall Street sharks "who would eat their grandmothers for breakfast if they could make some money out of it," as author John H. Davis puts it.

Today, it’s also why investing has taken such a unique turn for me.

See, when I was managing money on Wall Street, I built fortunes for the likes of Credit Suisse, Citicorp, and Goldman Sachs.

But instead of walking away from those shark-infested waters and selling my secrets to the highest bidder (like some do), I’ve been quietly delivering the intel I gathered to a small circle of do-it-yourself investors just like you.

And I am doing it in a way that is truly unique — by giving folks the chance to invest alongside an experienced Wall Street vet who knows how to outfox the foxes.

I use my experience and network of contacts for finding special situations that aren’t yet on Wall Street’s radar, so they're right there with me as new opportunities emerge.

It’s truly exhilarating.

"$68,000 in gains"

double-down-arrow-white

Thousands of people are already using this revolutionary method for investing.

Just take a look at what they have to say...

Butch G., a retired accountant, wrote in to tell me:

“Thanks is insignificant for the assistance you have given us. We had lost 30+% of our retirement portfolio [prior to subscribing] and are now on track to be where we were in 2006. God bless you, your family and your staff.”

Steve A., an attorney, wrote:

“Charles has made me money... $68,000 in gains from his recommendations.”

Dan K. says:

“Charles... Ninety percent of my portfolio is strictly in line with your picks. I speculate with the other 10%... but mostly, my retirement is in your hands so thanks for the fine job you are doing. I hope you have no intentions of retiring yourself anytime soon.”

Now, Dan’s a chief financial officer of a $400 million company, allocates money to outside managers for other people, and graduated from Columbia University. Yet, when it comes to his own personal retirement account, he follows my recommendations.

Today, I'm inviting you to join our investment community and to start reaping the profits it provides.

The best part is that anyone can use or simply follow my revolutionary way of investing.

But I'm encouraging you to get started right now.

The New York Times says it’s “a new era in medicine that is coming faster than most realize.”

This particular opportunity is so massive — and so potentially lucrative — that it could pass you by in a matter of days...

"The excitement among doctors is palpable"
— The Washington Post

“This is a major advance,” says Dr. Malcolm A. Smith of the National Cancer Institute.

And Dr. Stephan Grupp of the Children’s Hospital of Philadelphia called this therapy “utterly transformative.”

Take patient Emily Whitmore of Harrisburg, Pennsylvania.

Emily had been diagnosed with leukemia at the age of six.

Her chemotherapy treatment had failed, and she'd been given just weeks to live.

So, her parents called local hospitals to see if there were any experimental treatments available.

Emily became the very first patient to receive the single-shot treatment.

“Our daughter was going to die and now she leads a normal life,” said Emily’s father, Tom.

It zapped her cancer in just two weeks!

As Tom said: “It will save thousands of children’s lives around the world.”

Of course, it’s not just children who are seeing life-changing results...

Bill Livinson, a 72-year-old retiree from New Jersey, had battled the disease for more than a decade.

Nothing had worked for him. So, after exhausting all the other treatment options, the doctors gave him the single-shot therapy.

“We were hoping for a little improvement,” says Bill.

But when the doctors read Bill’s biopsy report, they were stunned: His cancer had been completely wiped out.

In fact, they didn't even believe the results. The doctors thought it had to be a mistake. So, they ordered Bill to take the test again.

But the results came back the same: The cancer was eliminated!

So, how exactly does it work? And why is it so revolutionary?

Set to Completely Replace Chemotherapy Within 5 Years

double-down-arrow-white

The core concept behind this treatment was actually inspired by a Nobel Prize-winning German doctor back in 1909.

His name is Dr. Paul Ehrlich.

He proposed the idea that our bodies are fighting constant battles with cancer and that, thankfully, most of the time we win.

In other words, cancerous cells are constantly forming in the body but our immune system, in most cases, keeps them at bay.

His theory sputtered along for decades, but today, it’s at the center of biotech’s hottest areas of research.

The mobilization of the human immune system in the battle against cancer...

Unlike chemotherapy, which kills cancer cells, this treatment works to boost your immune system in order to fight disease.

Essentially, it turns your blood into what scientist Dr. Carl June calls a “true living drug.”

It’s engineered from about a single ounce of a patient’s own blood.

This “living drug” grows inside the body into an army that destroys tumors and “melts away” cancer.

And it’s delivered in a single shot!

So, instead of treating cancer, scientists have developed a way to treat immune systems.

As Wired points out: “The secret to curing cancer could lie in treatments that 'supercharge' immune systems.”

It’s particularly effective against some of the deadliest types of disease, including lung and skin cancers.

Dr. Daniel F. Hayes, president of the ASCO, says: “This approach can be effective against a wide range of hard-to-treat advanced cancers previously considered intractable.”

Treatments and drugs for diseases that were once thought to be impossible to cure have been extremely profitable.

For example, the drug Yervoy, approved in March 2011 to treat metastatic melanoma, pushed Bristol-Myers Squibb stock toward record highs, handing investors nearly three times their investments.

Then there’s the drug Kalydeco, approved in January 2012 to treat cystic fibrosis, which helped to push Vertex Pharmaceuticals' stock up almost fourfold.

Revlimid, approved in December 2005 to treat multiple myeloma (a blood cancer), sparked Celgene’s stock run-up more than ninefold:

paic-cancer-blaster-celgene

Viread, approved in October 2001 to treat HIV, helped push Gilead Sciences’ stock up 25-fold:

paic-cancer-blaster-gilead

That’s a 2,006% increase.

And Epogen, licensed in June 1989 to treat anemia, sparked Amgen’s stock rise from $0.90 to $186 today:

paic-cancer-blaster-amgen

That’s an incredible 20,566% rocket ride, enough to turn a $5,000 investment into over $1.03 million!

Of course, as with all investments, past performance doesn’t guarantee future gains.

But there’s simply no denying the power that major medical developments have on a company’s stock price.

I simply wanted to show you the sheer power of a much-needed medical solution...

Think of the Investment Potential

Recently, the FDA made what they called a historic decision.

It agreed that the single-shot therapy developed by the $200 billion pharmaceutical giant Novartis should be approved for use outside of clinical trials.

It became official on August 30, 2017.

But everything is just getting started...

“This is a brand new way of treating cancer,” says Dr. Stephan Grupp.

“No one ever thought it would be possible to commercialize a therapy like this,” says Dr. Carl June.

It’s expected that the $108 billion firm Gilead Sciences will receive approval in the coming months.

And while there will be a number of ways to profit in the coming years, there will not be another opportunity like the one before you today.

If you were to make only one biotech investment in the next decade, this small Boston-based company is it.

I have never been more certain about anything in my entire life.

Here are the details...

Dr. Kenneth Anderson of Dana-Farber Cancer Institute in Boston called the results of the treatment study very remarkable.

And not just for how many patients responded but also for how well...

As Dr. Carl June says, its very rare to see everyone respond to a treatment.

It's cracked a seemingly uncrackable code.

As JPMorgan says of this company in a recent report: [It] is one of the more potentially transformative and disruptive companies weve come across in some time.

This tiny company’s revenue last year was only $26 million. But once its treatment hits the market, it could deliver a first-year revenue of $500 million.

So, we’re talking about an incredible revenue jump of 1,823%.

But remember...

That would still represent just a fraction of the market for this cancer therapy, which is projected to reach $202 billion.

So, from year two on, revenue could soar many multiples higher as the company gets a larger piece of the pie.

The upside is impossible to ignore...

The Market Is White-Hot!

double-down-arrow-white

The FDA approving the single-shot treatment for use outside of clinical trials could set everything in motion — rapidly.

Very soon, the 14 million people who are diagnosed with cancer each year may be able to walk into their doctor’s office, receive a simple shot, and walk out with the peace of mind knowing that they’ve conquered the disease.

Millions and millions of lives could be saved. And we could finally win the war on cancer while also being able to reap the financial rewards when these treatments are brought to market.

In short, what we have today is the rare chance to get in on the ground floor of a medical marvel.

One that already demonstrates a stunning potential to save lives.

To put it bluntly, the potential for this stock is greater than anything I’ve seen in my entire career.

And there’s yet another way that this company could hand you a massive payday...

See, these tiny biotech firms are quickly becoming takeover targets for pharmaceutical giants.

And the reason is simple: The partnerships make sense. Biotechs need cash infusions to bring their products to market; pharmaceutical companies need more products in their pipelines.

Gilead Sciences recently bought out Kite Pharma, Inc. to gain access to their new immune-boosting cancer therapy treatment.

Gilead paid a tidy $11 billion for the company.

Reni Benjamin, an analyst at Raymond James and Associates, says the buyout “heralds big biotech’s view regarding the promise of [single-shot] therapy, opening the door for more favorable deals going forward.”

Much like this Boston-based company’s single-shot treatment that I’ve been telling you about, Kite’s product is on the brink of becoming commercially available in America. And it’s expected to generate $1.7 billion in first-year sales.

Thanks to this blockbuster buyout, Kite Pharma’s shareholders could’ve walked away with 157% gains after just three months.

Here’s another example: Bristol-Myers Squibb bought out small biotech Inhibitex for $2.5 billion.

The market cap for Inhibitex doubled in a flash:

paic-cancer-blaster-inhibitex

Shareholders made a killing: 1,016% gains within four months.

My point is that even if the stock I’ve been telling you about gets bought out, you could still make a retirement fortune from it.

And besides its single-shot therapy, this company has multiple business opportunities that make it attractive to a large pharmaceutical juggernaut.

I'm looking at this as the ultimate win-win scenario.

Here’s what it all boils down to...

The richest, smartest investors in America, like Gates, Bezos, Michael Bloomberg, and Sean Parker, are investing in this revolutionary therapy.

And I'm suggesting that you do the same — immediately. It’s only a matter of time before word spreads.

When this happens, and it will...

paic-cancer-blaster_report

It will be too late: You’ll be left fighting for the table scraps.

In just a moment, I’m going to tell you how to secure your FREE copy of a timely new report that I’ve put together on this new breakthrough. It’s called "How to Make 10 Times Your Money on the Single-Shot Cancer Blaster."

In it, you learn this little gem's ticker symbol and up to what price to buy it.

But I’m not stopping there...

Welcome to the Club

parkave-charles-nyc-backdrop

As I said, my name is Charles Mizrahi.

I’ve spent over 35 years first on Wall Street and then managing money for some of the most powerful investment firms like Goldman Sachs, Credit Suisse, and Citicorp.

Today, I am the director of a far more prestigious organization called Park Avenue Investment Club. It's arguably the world’s most powerful wealth-building society.

To give you some background information on it, 740 Park Avenue in New York City is what’s known as “the billionaire’s address.”

Oil tycoon John D. Rockefeller, financier Saul Steinberg, and Blackstone founder Steve Schwarzman have all hung their hats in that building. In fact, they’ve all lived in the very same apartment!

It’s one of the most expensive addresses in the entire world. There’s a reason why New York City is home to more millionaires and billionaires than any other city on the planet...

It's because people of power and wealth congregate together, they use each other's business contacts, they socialize together...

And that's how the best business deals and ideas come about.

Over the years, I’ve had the good fortune to be friends with, spend time with, and pick the brains of some of the greatest investors of the last 50 years.

I’m talking about guys like:

  • Don Yacktman, manager of over $30 billion.

  • Bruce Kovner, founder of Caxton Associates and manager of approximately $5 billion.

  • "Ace" Greenberg, legendary trader-turned-executive of Bear Stearns.

I’ve seen business relationships and contacts develop and lead to multibillion-dollar deals.

Of course, not everyone can live at 740 Park Avenue. Just to be considered for an apartment in the building, you need a liquid net worth of $100 million. It’s very exclusive.

But by joining Park Avenue Investment Club, you’ll get all of the exclusive insights, contacts, and access that I've gained from more than 35 years on Wall Street as a floor trader, money manager, and hedge fund manager.

I created Park Avenue Investment Club with a specific goal in mind: To give you the tools, the knowledge, and the approach for turning you into a millionaire.

And not just once, either, but a millionaire several times over...

For me, making money has a very different meaning than it does for most people. I didn’t want to buy houses or fancy cars or watches. That’s not what’s important to me...

The Real Meaning Behind Having Wealth

When I went to work on Wall Street at age 20, there were two things that I wanted to have when I got wealthy.

The first thing I wanted to have was freedom — freedom from worrying about where my next dollar would come from, freedom from debt, and the freedom to do what I wanted, whenever I wanted. I didn’t want to have to answer to a boss or watch how I spent my money.

The second thing that I wanted to have was the ability to give back. And here’s why...

My three brothers and I attended private school, but because my father was a warehouse manager, he couldn’t afford the tuition.

So, once a year he had to go in front of the scholarship committee where they would scrutinize every nickel he made. And then they'd tell him how much he would have to pay.

And this is why I swore that when I got older and started making money, I wouldn't be the recipient of charity; I would be the giver.

It's why I joined many charitable organizations. I’ve sat on their executive boards and I’ve even started some myself.

So, those were the two things that drove me: The freedom to do what I wanted and the ability to give to others.

Having wealth could mean something totally different to you.

It could mean traveling, spending more time with your loved ones, buying a boat to sail around the world.

It doesn’t really matter to me what you decide to do with your wealth.

The Park Avenue Investment Club approach is designed specifically to help you reach your investment goals.

And also to prevent you from deviating from your path to wealth...

Club members demand only the finest research and the most compelling opportunities. And that's precisely what they receive.

We have no relation to any outside organization. My recommendations are based on independent research and years of experience in the trenches — not backroom deals between corporations and brokerage houses.

I’ve delivered hundreds of profitable ideas to members throughout the years...

Finding the Kind of Plays Wall Street Insiders Dream Of

double-down-arrow-white

I use my experience and network of contacts to find special situations that aren’t yet on Wall Street’s radar.

Here’s a short story to help you understand what I’m talking about...

Back in 2012, I went to lunch with a hedge fund analyst whom I’d known since he'd graduated college and tried to work for me. This kid was sharp.

He told me that a major defense contractor spun off its shipbuilding division. Since it was a spin-off, it wasn’t widely followed. And since it had just started trading, his fund couldn’t invest in it.

I went back to my office, rolled up my sleeves, and did my research. What I uncovered made me smile from ear to ear.

The first thing that caught my eye about this spin-off company was that it was the sole supplier of nuclear-powered submarines and aircraft carriers to the U.S. Navy. The second was that 70% of the company’s billion-dollar annual revenue stream had no competitors!

And after poring over the company’s documents, I discovered it had $16.3 billion in backlogged orders — more than three years' worth of sales.

But here’s the kicker: The company was about to shed a number of low-margin contracts and had replacement work — at double the profit margin — already on the books.

Immediately, I saw dollar signs, and not just for the company...

I sent my subscribers a buy alert and told them to buy the stock anywhere below $40 a share.

After a few short weeks, the stock started to move higher, and it’s been on a tear ever since...

I still have the stock in the portfolio. It’s trading in the $200 range, and we’re up more than 400%.

This is precisely the type of "special" situation that Wall Street insiders personally invest in and also the type of opportunity I tip my readers off about regularly.

This includes under-the-radar opportunities like the cancer therapy, which you’ll discover in my newest research report, called "How to Make 10 Times Your Money on the Single-Shot Cancer Blaster."

I’d like to send it to you for free when you agree to accept this limited-time offer for joining our unique organization.

But that’s not all...

Benefits You Can’t Put a Price On

Here’s more of what you’ll get as a member:

  • A new issue of Park Avenue Investment Club every single month. These issues give you new buy, sell, or hold recommendations and a full analysis behind each of my new picks. You’ll always know what steps to take and when to take them.

  • Special Park Avenue Investment Club alerts. Sometimes, a new buy or sell recommendation simply can’t wait for the monthly issue, so I’ll send you these alerts right away. Plus, I’ll also give you updates on our current positions.

  • Unrestricted 24-7 access to the members-only Park Avenue Investment Club archives. Here, you’ll find all of my monthly issues, special reports, portfolio updates, and my model portfolios — including my latest batch of stocks, which are the kind Wall Street insiders dream about.
  • Access to a powerful customer service support team. Our service team is standing by to answer any of your questions anytime between 9:30 a.m. and 4:30 p.m. (ET).

  • The freedom to do what you want, when you want. This is all made possible because of your wealth-building wealth.

  • A heck of a lot of fun, too!

Plus, I’ll make sure that my team sets you up with members-only access to each new wealth-building resource we develop, for example:

  • Access to the Park Avenue Investing Academy (a 10-video series). With this series, you learn how to “buy dollar bills for $0.50.” It’s how I built my legacy of success, and it's where you learn how to take my success to make it your own wealth-building story.

  • “5 Biggest Keys to Investment Success." This video of a recent investment boot camp I hosted is where I reveal my biggest investing principals. And it's just one of the presentations included in this exclusive investing seminar.

Also, because you’ll be joining as a charter member through this invitation, I have one more gift that I’d like to send to you as soon as I hear from you...

  • A copy of my brand new report: “The Leader of the $50 Trillion Deep Learning Revolution.” From health care to transportation to e-commerce, artificial intelligence is disrupting nearly every industry on the planet. But there’s one breakthrough technology at the center of it all. This report shows you how to turn $1,000 into $673,000 over the next decade.

paic-deep-learning-revolution_report

Again, once you sign up to join Park Avenue Investment Club, you’ll get access to me, my contacts, and also my years of experience as a floor trader, money manager, and hedge fund manager.

You’ll no longer have to sit in front of a computer screen all day, stressing out over every wiggle on a chart. You won’t need to track stocks daily. You can go about your day, live your life, and still make higher returns than most who are glued to their trading screens all day long.

Unsurprisingly, our members are more than pleased.

I already told you about Steve A. — the investor who’s already made $68,000 from following my recommendations. That’s more than what most people make over the course of a year from working full time. What could you do with a $68,000 windfall?

Then there’s Eric S. who reached out to say:

“I have seen many newsletters and daily stock tip e-mails... but I have the most confidence and so far the highest gains with your system.”

Profits like these could be yours, too. In just a few moments, you're going to have the chance to book strings of triple-digit profits like these:

  • 419% GAIN on HII
  • 448% GAIN on ATRI
  • 283% GAIN on TJX
  • 238% GAIN on GD
  • 255% GAIN on MSFT
  • 251% GAIN on BKE
  • 193% GAIN on HCC
  • 188% GAIN on DAKT
  • 176% GAIN on COH

And, while I’m thrilled that these winners made cumulative gains of 2,451%, I’m also confident that they'll look like peanuts compared to what’s ahead...

With moneymaking events rapidly unfolding before our very eyes, there’s never been a better time to join Park Avenue Investment Club than right now.

This cancer breakthrough could potentially save millions of lives every single year.

It’s already saved the lives of people who are suffering from advanced stages of leukemia, lymphoma, multiple myeloma, and numerous other cancers.

It’s nothing short of a medical miracle — something once thought to be impossible.

And it’s grabbed the attention of the world’s top billionaires, who are pouring millions into this breakthrough treatment.

I don’t want anything to hold you back from what’s at hand.

That’s why I’ve set the membership cost of the Park Avenue Investment Club at a ridiculously low price...

Now, back in my money manager days, a rich client would give me money, I’d manage their account, and they’d pay the standard "two and twenty" — a 2% fee for assets under management and 20% of the profits.

Since I had a $1 million minimum, it meant that the LEAST amount my clients would pay me in a year was $20,000. This was for the same expertise that I’ll be sharing with you from now on...

But that's not why I started the Park Avenue Investment Club. I’m sick of seeing overpriced nonsense being pushed as reputable stock research, and I’m also sick of mom-and-pop investors getting taken to the cleaners.

As you may know, many so-called "experts" charge $5,000 or $10,000 for what is essentially an unfollowable portfolio or for one with a track record so divorced from reality that it might as well be listed as fiction.

You deserve better than that. So, the price for gaining full access to Park Avenue Investment Club is just $199.

Frankly, I think it’s a steal at that price.

But I know that, for many Americans, times are tough. I didn’t come from money, and my family worked hard to make every dollar go as far as it could. And the dollar certainly doesn’t stretch as far as it used to.

So, here’s what I’ve decided to do...

For a limited time, I’m allowing you to join for only $99. That’s over half off the normal price!

Here's How to Get Started

If you’d like to join me in the medical revolution ahead — and in all the best profit opportunities I uncover as they emerge — then the best thing to do now is to sign up for Park Avenue Investment Club.

I’m confident that you’ll find joining Park Avenue Investment Club to be the best financial move you’ll ever make.

Many of our members are regular folks with only $10,000 to invest, and others are multimillionaires.

No matter what investment level you are, the key is to take control of your finances and to grow money now.

And I have no doubt that Park Avenue Investment Club and the principles we follow will help with starting you down that road today.

But you need to act fast. The speed at which this emerging opportunity is moving will pass by those who hesitate.

“The field is moving very fast,” says Dr. Jason Luke of the University of Chicago.

Remember: This breakthrough is set to replace chemotherapy as the standard treatment for cancer within the next five years.

As soon as we receive your acceptance, we’ll rush to send you this special report by email and also all the other wealth-building resources that I’ve told you about.

Simply click on the “Join Now” button below to get started.

I look forward to having you as a member of the club.

Sincerely,

Charles Mizrahi signature

Charles Mizrahi
Founder, Park Avenue Investment Club

join-now-blue

P.S. Act now for more than HALF OFF! Respond to lock in your premier membership for only $99 — a discount of over 50%. But you'll need to sign up today. Click here to join now. This is a limited-time offer that could expire at any time and without notice.